



US 20210324003A1

(19) United States

(12) Patent Application Publication

ANDRABI et al.

(10) Pub. No.: US 2021/0324003 A1

(43) Pub. Date: Oct. 21, 2021

(54) SIV ENVELOPE TRIMER

A6IK 39/39 (2006.01)

(71) Applicant: The Scripps Research Institute, La Jolla, CA (US)

A6IK 9/127 (2006.01)

A6IK 9/51 (2006.01)

A6IK 47/08 (2006.01)

A6IK 47/10 (2006.01)

G01N 33/569 (2006.01)

(72) Inventors: Raiees ANDRABI, La Jolla, CA (US); Dennis BURTON, La Jolla, CA (US)

(21) Appl. No.: 17/231,415

(52) U.S. Cl.

CPC C07K 5/08 (2013.01); C12N 7/00

(2013.01); C12N 15/86 (2013.01); A6IK 39/21

(2013.01); A6IP 31/18 (2018.01); A6IK 39/39

(2013.01); A6IK 2039/545 (2013.01); A6IK

9/51 (2013.01); A6IK 47/08 (2013.01); A6IK

47/10 (2013.01); G01N 33/56988 (2013.01);

C12N 2740/15022 (2013.01); C12N

2750/14143 (2013.01); A6IK 9/127 (2013.01)

(22) Filed: Apr. 15, 2021

ABSTRACT**Related U.S. Application Data**

(63) Continuation-in-part of application No. PCT/US2019/056867, filed on Oct. 18, 2019.


(57)

(60) Provisional application No. 62/747,650, filed on Oct. 18, 2018.

The present application relates to epitope-targeted SIV and HIV vaccines. The invention provides novel envelope glycoproteins which may be utilized as HIV-1 vaccine immunogens, antigens for crystallization, and for identification of broadly neutralizing antibodies. The invention encompasses preparation and purification of immunogenic compositions which are formulated into vaccines of the present invention.

Specification includes a Sequence Listing.

A



V1V2 (P3)

V1V2 (P1)